Company intelligence / Profile preview

PsyLabs

South Africa

Ownership: Public · PBM
Development stage: Other

Overview

PsyLabs has developed pharmaceutical-grade, nature-derived psilocybin, successfully exported to Canada, UK, Portugal, Slovenia, and supplies clinical and research markets; early-stage results support high-grade APIs, with no independent clinical trial outcomes from PsyLabs reported to date[3][4].

Therapeutic areas: Psychiatry
Modalities: Small moleculeNatural productExtract
Industry: Biotech

Drug pipeline

1 asset

Iboga-magnesium spray

Preclinical

Partnerships

Psyence Biomed (Clinical trial supply, equity stake, exclusive licensing for API program)[1][2][4]UK-based Contract Manufacturing Organization (CMO, pharma-grade production)[2][4]

Beyond the preview

Go deeper on PsyLabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PsyLabs.

Explore the full profile